Johnson & Johnson (NYSE:JNJ) was downgraded by Vetr from a “hold” rating to a “sell” rating in a research note issued to investors on Friday. They currently have a $129.62 target price on the stock. Vetr‘s price target suggests a potential downside of 5.27% from the stock’s previous close.
Several other analysts have also commented on the stock. UBS AG reaffirmed a “buy” rating and issued a $148.00 price objective (up previously from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $125.00 to $130.00 in a research report on Wednesday, September 20th. BMO Capital Markets reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research report on Friday, September 1st. Alembic Global Advisors lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Finally, BidaskClub raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $135.98.
Johnson & Johnson (JNJ) opened at 136.83 on Friday. The company has a 50-day moving average of $132.44 and a 200-day moving average of $130.12. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.52. The firm has a market cap of $367.25 billion, a price-to-earnings ratio of 23.15 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.74 earnings per share. Equities research analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Vetr Inc. Downgrades Johnson & Johnson (JNJ) to Sell” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2956266/vetr-inc-downgrades-johnson-johnson-jnj-to-sell.html.
In related news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the business. Harding Loevner LP purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. grew its stake in Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares in the last quarter. Mountain Capital Investment Advisors Inc purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $124,000. Finally, Harel Insurance Investments & Financial Services Ltd. grew its stake in Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after buying an additional 841 shares in the last quarter. 65.90% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.